Compare Intel Corp (INTC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Sanofi SA — how do they compare? Intel Corp trades at $104.7 (market cap $566.04B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Intel Corp is far larger — about 5.9× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and Sanofi SA for 94 Days on average.
| INTC | SNY | |
|---|---|---|
Market Cap | $566.04B | $95.18B |
Volume | 118,475,837 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $140.94 | $52.34 |
52-Week Low | $33.62 | $39.51 |
Typical Hold Time | 116 Days | 94 Days |
Enterprise Value | $586.85B | $114.48B |
Dividend Yield | 2.24% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $107.08, down 5.34% over 24 hours, with a bullish technical breakout pattern despite near-term bearish momentum indicators. The company reported three consecutive quarterly EPS beats but posted a net loss of -$267 million in 2025, with revenue declining to $52.85 billion. Intel Foundry's 31% year-over-year growth in Q2 2026 and High-NA chipmaking progress highlight its strategic pivot, though profitability remains challenged with a negative net margin of -0.51%.
Intel's outlook balances a 222% stock surge in 2026 against high valuation multiples and persistent margin pressures. Investment opportunities lie in its foundry turnaround and AI infrastructure positioning, but risks include intense competition, execution challenges, and debt levels. Analyst consensus is cautious with a $111.72 price target and 54% hold ratings, signaling wait-and-see sentiment amid volatile fundamentals.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
